Balance Sheet
Cash Flow Statement
AmortizationAmortizationAmortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in Working CapitalChange in Working CapitalDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Depreciation & Amortization (CF) (2020 - 2025)

Legend Biotech filings provide 6 years of Depreciation & Amortization (CF) readings, the most recent being $2.1 million for Q3 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 9.87% to $2.1 million in Q3 2025 year-over-year; TTM through Dec 2025 was $6.7 million, a 37.26% decrease, with the full-year FY2024 number at $10.7 million, changed 0.04% from a year prior.
  • Depreciation & Amortization (CF) hit $2.1 million in Q3 2025 for Legend Biotech, down from $2.3 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $3.2 million in Q1 2022 to a low of -$20000.0 in Q4 2021.
  • Median Depreciation & Amortization (CF) over the past 5 years was $2.7 million (2023), compared with a mean of $2.4 million.
  • The widest YoY moves for Depreciation & Amortization (CF): up 12505.0% in 2022, down 38.93% in 2022.
  • Legend Biotech's Depreciation & Amortization (CF) stood at -$20000.0 in 2021, then surged by 12505.0% to $2.5 million in 2022, then rose by 9.88% to $2.7 million in 2023, then increased by 0.62% to $2.7 million in 2024, then dropped by 21.76% to $2.1 million in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $2.1 million (Q3 2025), $2.3 million (Q2 2025), and $2.3 million (Q1 2025) per Business Quant data.